| Bioactivity | DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer[1]. |
| Name | DOTA-CXCR4-L |
| Sequence | cyclo[{d-Tyr}-{d-(NMe)Orn}-(HYNIC-DOTA)-Arg-{Nal}-Gly)] |
| Shortening | cyclo[{d-Tyr}-{d-(NMe)Orn}-(HYNIC-DOTA)-R-{Nal}-G)] |
| Formula | C58H78N16O14 |
| Molar Mass | 1223.34 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Luna-Gutiérrez M, et al. Preclinical evaluation of the theranostic 68 Ga/177 Lu-[DOTA-CXCR4-L] pair [C]//Trends in Radiopharmaceuticals (ISTR-2019). Proceedings of an International Symposium. Programme and Abstracts. 2020. |